TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of follicles measuring ≥18 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower rate of violence-related behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: youth reports of normative beliefs supporting aggressive behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: parent reports of youth bullying behaviors
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Overall patient exit interview scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intervention fidelity of special intervention providers
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: A‐line ARX index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of death from any cause or hospitalization for any reason
Endpoint domain: Mortality/survival
Primary endpoint: Risk of worsening heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: R(+)‐Pindolol CLR values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: S(‐)‐Pindolol CLR values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Beta-blocking activity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Student performance in simulator-based OSCE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients perception of absorption of the medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Medication side effects
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: actual fluid loss not exceeding the target fluid loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient global assessment improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: central venous pressure decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Survival rates
Endpoint domain: Mortality/survival
Primary endpoint: First time failure rate for molar bonds
Endpoint domain: Mortality/survival
Primary endpoint: Molar enamel demineralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent experiencing 50% improvement in depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean performance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-progression survival (PPS)
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of complete response (no PONV, no rescue medication)
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of impression techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvement in signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fulfillment of diagnostic criteria for somatoform pain disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Somatization symptom checklist scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of sexual abuse
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Fasting LDL-C concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Fasting apoB100 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Reduction in glycated hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CAARS subscales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total hip BMD reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Lumbar spine BMD stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Femoral neck BMD reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: peak speed of the fingertip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: path curvature for the fingertip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First perception of intestinal balloon distension pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Plasma PP levels response to insulin hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS28(CRP) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SDAI improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discomfort caused by lidocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score related to endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal decongestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total mean effective dose (mSv)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Obsessive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived confidence in task performance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pulmonary capillary wedge pressure decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systemic vascular resistance decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Neurodevelopmental impairment (NDI) or death
Endpoint domain: Mortality/survival
Primary endpoint: Significant gross motor impairment or death
Endpoint domain: Mortality/survival
Primary endpoint: Maximum dose delivered to the PTV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation delivered to the rectum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation delivered to the femoral heads
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete resolution of disease at day 20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in FI symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in mite allergen exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of moderate to severe NPSAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of POD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in balance and trunk performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confidence scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SIRs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraoperative tourniquet pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postsurgical analgesic needs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pancreatic or peripancreatic infections
Endpoint domain: Adverse events/effects
Primary endpoint: Requirement for surgical intervention
Endpoint domain: Surgical and medical procedures outcomes
Primary endpoint: Recurrence of epithelial defects
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in conjunctival hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in conjunctival discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of subjective symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: health behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: health problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ablation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: overall procedure duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: total energy delivered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting serum proinsulin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Knowledge of diabetes and problem solving ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improvement in general cognitive functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to laryngoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: depression level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: sputum inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fasting glucose increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of CRBSI per 1000 catheter-days
Endpoint domain: Adverse events/effects
Primary endpoint: Total hospital cost increase associated with CRBSI
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: ICU cost increase associated with CRBSI
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Fractional Synthetic Rate (FSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appropriate filling of root canals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: treatment benefit in ocular rosacea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in convulsive seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in skeletal cephalometric landmarks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QT indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharyngeal collapse frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Head height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Head movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sputum smear conversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: culture conversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Altered full field VEPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Abnormal CPLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in daily 'off' time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in daily 'on' time without dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median length of hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased work of breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute rejection percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum creatinine values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Positive response rate on follow-up head-up tilt test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in endometrial thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration‐versus‐time curve of glyburide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration‐versus‐time curve of bosentan and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sympathetic nerve activity (SNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NAFLD as an independent predictor of CVD outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean variability of mean arterial blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cost savings associated with alvimopan use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Lymphocyte catalase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Erythrocyte glutathione reductase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Erythrocyte superoxide dismutase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction of knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed Up-and-Go Test (TUGT) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of single daily dosing compared to multiple daily dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean drug adherence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pruritus value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery from PPHN
Endpoint domain: Mortality/survival
Primary endpoint: Lactate concentration in coronary sinus blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Echocardiographic grading of left ventricular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response rate based on HAM-D scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate based on CGI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Demodex count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall comfort improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in dryness symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in phosphorus serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in PTH serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in NTx urine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accuracy of navigation system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Setup time for navigation system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Good Drug Effect ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Capsule Liking ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Performance in drug choice test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum drug-induced reduction in mean plasma cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: systemic exposure to FP resulting in half the maximum possible reduction in plasma cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum bioactive IGF‐I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total IGF‐I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum IGF‐binding protein‐1 (IGFBP‐1) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ambulation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of support for the affected side
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Step length and walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global psychopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: service user involvement in treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dialysate-to-plasma ratio of creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Dialysate-to-plasma ratio of urea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Ultrafiltration volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: RE response in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Chylomicron cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Post-prandial HDL-cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: agitation severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first occurrence of stroke, transient ischemic attack, or systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: median event-free survival
Endpoint domain: Mortality/survival
Primary endpoint: median time-to-tumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI-I responder rate
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sleep outcomes improvement
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Frequency of diarrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Neurological outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: plasma total antioxidant capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased risk of prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: BA diameter increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: distensibility coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rates of acceptable cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of short cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overestimation of root canal length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histologic improvement in elastic tissue content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Actuarial probability of remaining free from rebleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic encephalopathy within 1 month
Endpoint domain: Adverse events/effects
Primary endpoint: 24-month mortality
Endpoint domain: Mortality/survival
Primary endpoint: period free of emergent hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in cardiometabolic risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decreases of ≥ 7% in overweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adhesion of isolated monocytes to endothelial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Generation of pro-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neutrophil recruitment into the alveolar space
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of data points completed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time taken to complete assessments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Risk of major events (cardiovascular death, myocardial infarction, and stroke)
Endpoint domain: Mortality/survival
Primary endpoint: Controlled ambulatory blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in hypochondriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of FFR measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: total diabetes distress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: total diabetes treatment satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life